Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Korea.
Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea.
J Clin Sleep Med. 2024 Jul 1;20(7):1173-1182. doi: 10.5664/jcsm.11126.
Despite its widespread use in patients with isolated rapid eye movement sleep behavior disorder (iRBD), the cognitive effect of clonazepam is uncertain. This study aimed to investigate the effect of cumulative clonazepam on cognitive function in patients with iRBD.
Demographic characteristics, baseline cognitive test, and most recent cognitive test information were collected retrospectively. Based on cumulative clonazepam doses, patients were classified into 4 subgroups: group 1, < 365 mg (1 mg × 1 year); group 2, 365 mg to < 1,095 mg (1 mg × 3 years); group 3, 1,095 mg to < 2,190 mg (1 mg × 6 years); and group 4, 2,190 mg or more. Cognitive test scores were calculated as scores adjusted for age, education, and sex.
This study included 101 patients with iRBD (63 males). Groups 1, 2, 3, and 4 had 14, 20, 32, and 35 patients, respectively. In within-group comparisons, follow-up Digit Span Backward test and the Trail Making Test A scores decreased in group 3, and follow-up Trail Making Test A and the Trail Making Test B scores decreased significantly in group 4. In the multiple regression analysis to determine influential factors on cognitive decline, cumulative clonazepam dose did not show a significant correlation with any cognitive domain. Follow-up cognitive function showed significant correlation only with baseline cognitive function.
Memory and executive functions tended to decline in patients with iRBD. However, there was no significant effect of cumulative clonazepam. There was no evidence that long-term use of clonazepam was related to cognitive decline in patients with iRBD.
Lee M, Kim TK, Hong JK, Yoon I-Y. Minimal effect of long-term clonazepam on cognitive function in patients with isolated rapid eye movement sleep behavior disorder. . 2024;20(7):1173-1182.
尽管氯硝西泮在孤立性快速眼动睡眠行为障碍(iRBD)患者中广泛应用,但它对认知的影响尚不确定。本研究旨在探讨累积氯硝西泮剂量对 iRBD 患者认知功能的影响。
回顾性收集患者的人口统计学特征、基线认知测试和最近的认知测试信息。根据累积氯硝西泮剂量,将患者分为 4 个亚组:组 1,<365mg(1mg×1 年);组 2,365mg 至<1095mg(1mg×3 年);组 3,1095mg 至<2190mg(1mg×6 年);组 4,2190mg 或更多。认知测试评分计算为年龄、教育程度和性别校正后的 z 评分。
本研究纳入 101 例 iRBD 患者(63 例男性)。组 1、2、3 和 4 分别有 14、20、32 和 35 例患者。在组内比较中,第 3 组的数字符号替换测试和连线测试 A 评分在随访时下降,第 4 组的连线测试 A 和连线测试 B 评分在随访时显著下降。在确定认知功能下降影响因素的多元回归分析中,累积氯硝西泮剂量与任何认知域均无显著相关性。随访认知功能仅与基线认知功能显著相关。
孤立性快速眼动睡眠行为障碍患者的记忆和执行功能呈下降趋势,但累积氯硝西泮无显著影响。没有证据表明长期使用氯硝西泮与孤立性快速眼动睡眠行为障碍患者的认知功能下降有关。